Survodutide
Also called BI 456906
What to know about Survodutide
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist being studied for weight and liver-related outcomes.
- How it may work
- GLP-1-receptor activity influences appetite and glucose regulation, while glucagon-receptor activity may increase energy expenditure and affect liver metabolism.
- What research found
- A 46-week phase 2 trial randomized 387 adults and reported dose-related weight reduction. Gastrointestinal events were common and discontinuations were higher at several active doses.
- What is not settled
- Larger and longer trials are needed to characterize rare events, cardiovascular outcomes, liver outcomes, and the risk-benefit balance of glucagon-receptor activity.
- Research and product status
- Survodutide remains investigational and has no licensed U.S. product as of this review.
Research reference
- Research amount range
- 0.6–4.8 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Model accumulation timescale
- ~30.0 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- The phase 2 obesity study measured body-weight change at 46 weeks and escalated the amount over time. It does not support a dependable first-week or first-month result.
- When to assess
- The studied outcome was judged over months, after escalation. Early appetite or scale changes are incomplete proxies and do not establish a personal success threshold.
- Conditions and limitations
- The trial context included lifestyle support and monitored escalation. No evidence establishes a special time of day, fasting requirement, or stacking partner.
- When to stop
- No consumer maintenance or quit rule is established for this investigational compound. Study oversight and safety rules—not self-directed escalation—governed continuation.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Survodutide describe 0.6–4.8 mg per administration. Descriptive only, not a recommendation.
About 6 days, with high albumin binding; supports once-weekly dosing.
Research schedule reference
Reported schedule context for Survodutide; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Lowest maintenance arm and the starting step; escalation limits gastrointestinal load. | 0.6 mg | Once weekly | SubQ |
| Step up | 2.4 mg | Once weekly | SubQ |
| Step up | 3.6 mg | Once weekly | SubQ |
| Highest armHighest maintenance in the phase-2 trial; reached by stepwise titration only as tolerated. | 4.8 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.74× single dose
- Time to steady state
- 30.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- le Roux CW et al., Lancet Diabetes Endocrinol 2024;12:162Phase-2 dose-finding of the GLP-1/glucagon dual agonist survodutide; weekly maintenance arms of 0.6, 2.4, 3.6 and 4.8 mg over 46 weeks in adults with obesity.